Although tyrosine kinase inhibitors (TKIs) induce a substantial cytogenetic and molecular response in all phases of CML, a minority of p230 positive patients have been treated with TKIs. This evidence concerns the gene GOLGA4 and chronic myelogenous leukemia, BCR-ABL1 positive.